Nobuhiko Hiraga
Overview
Explore the profile of Nobuhiko Hiraga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, et al.
PLoS One
. 2017 Mar;
12(3):e0172412.
PMID: 28253324
Interferon (IFN) inhibits hepatitis C virus (HCV) replication through up-regulation of intrahepatic IFN-stimulated gene expression but also through activation of host immune cells. In the present study, we analyzed the...
12.
Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, et al.
Cell Mol Gastroenterol Hepatol
. 2017 Feb;
1(5):516-534.
PMID: 28210698
Background & Aims: Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Liver cancer tumor specimens are difficult to obtain, and noninvasive...
13.
Uchida T, Imamura M, Kan H, Hiraga N, Hayes C, Tsuge M, et al.
J Gen Virol
. 2017 Feb;
98(5):1040-1047.
PMID: 28141486
Urokinase-type plasminogen activator/severe combined immunodeficiency (uPA/SCID) mice transplanted with human hepatocytes are permissive for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, one of the problems affecting...
14.
Kan H, Imamura M, Uchida T, Hiraga N, Hayes C, Tsuge M, et al.
J Infect Dis
. 2016 Sep;
214(11):1687-1694.
PMID: 27651415
Background: Although treatment-emergent NS3/4A protease inhibitor (PI)-resistant variants typically decrease in frequency after cessation of PI therapy in patients with chronic hepatitis C virus (HCV) infection, HCV susceptibility to PIs...
15.
Yamamoto S, Fukuhara T, Ono C, Uemura K, Kawachi Y, Shiokawa M, et al.
PLoS Pathog
. 2016 May;
12(5):e1005610.
PMID: 27152966
Scavenger receptor class B type 1 (SR-B1) and low-density lipoprotein receptor (LDLR) are known to be involved in entry of hepatitis C virus (HCV), but their precise roles and their...
16.
Aizawa S, Okamoto T, Sugiyama Y, Kouwaki T, Ito A, Suzuki T, et al.
Nat Commun
. 2016 May;
7:11379.
PMID: 27142248
Signal-peptide peptidase (SPP) is an intramembrane protease that participates in the production of the mature core protein of hepatitis C virus (HCV). Here we show that SPP inhibition reduces the...
17.
Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, et al.
J Gastroenterol
. 2016 Mar;
51(11):1073-1080.
PMID: 26943168
Background And Aims: Interferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently...
18.
Morio K, Imamura M, Kawakami Y, Morio R, Hatooka M, Kan H, et al.
Hepatol Res
. 2016 Feb;
46(12):1256-1263.
PMID: 26916827
Aim: Polymorphisms in the ITPA gene influence anemia during peg-interferon (PEG-IFN) and ribavirin (RBV) therapy, but their effects during triple therapy with simeprevir, PEG-IFN, and RBV are not sufficiently known....
19.
Tsuge M, Hiramatsu A, Shinohara F, Nakano N, Nakamura Y, Hatooka M, et al.
Hepatol Res
. 2015 Nov;
46(9):944-8.
PMID: 26613201
Recently, treatments for chronic hepatitis C virus (HCV) infection have been drastically improved by the development of direct-acting antiviral agents. In September 2014, dual oral therapy using daclatasvir (DCV) and...
20.
Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, et al.
Hepatol Res
. 2015 Nov;
46(8):758-64.
PMID: 26574180
Aim: Although interferon (IFN)-free antiviral therapy is expected to improve the treatment response for chronic hepatitis C, the effect on liver function and liver fibrosis is unknown. In this study,...